Chemical Raw Materials
Inorganic Chemistry
- Inorganic Salt
- Inorganic Base
- Inorganic Acid
- Oxides and Peroxides
- Graphene
- Silica Gel
- Metal Ore
- Coating Material
- Other
Chemical Reagents
- Organic Reagent
- Silane Reagent
- Chiral Chemical Reagents
- Grignard Reagent
- Fluorine Reagent
- Deuterium Reagent
- Other
Pesticide Raw Materials
- Herbicide
- Insecticide
- Fungicide
- Plant Growth Regulator
- Pesticide Intermediates
- Feed Additives
- Food Additives
Daily Chemicals
Hazardous Chemicals
Phone: 86-13209521394
Mail: sales27@interlgroup.com
Add: Room 305 , 3/F , Haipai Decoration Office Building , Yudu Avenue , Yuncheng , Shanxi
Sunitinib Malate powder Raw Materials CAS 341031-54-7
Product Overview:
Sunitinib Malate powder is a new oral multi-target anti-tumor drug, belonging to the multi-target tyrosine kinase inhibitor, the product name suntent, which was successfully developed by Pfizer in the United States. Sunitinib Malate has dual anti-tumor effects. Sunitinib Malate is the only drug to break through the 2-year survival of advanced kidney cancer, and has a core position in the treatment of renal cell carcinoma and gastrointestinal stromal tumor. It was launched in the United States in February 2006. Sunitinib Malate is the first anti-cancer drug approved by the United States FDA to treat two diseases at the same time.
Sunitinib Malate powder Raw Materials CAS 341031-54-7 Attributes
MF:C26H33FN4O7
MW:532.57
EINECS:638-825-9
Specification:Sunitinib Malate powder
Sample:Sunitinib Malate powder
Brand:Sunitinib Malate powder
Appearance: powder
Storage: Cool Dry Place
Brand: chemical Raw Materials
Shelf Life: 2 Years
Test Method: HPLC
Sunitinib Malate powder Raw Materials CAS 341031-54-7 Details
Uses and synthesis of Sunitinib Malate powder
Sunitinib Malate powder is a new oral multi-target anti-tumor drug, belonging to the multi-target tyrosine kinase inhibitor, the product name suntent, which was successfully developed by Pfizer in the United States. Sunitinib Malate has dual anti-tumor effects. Sunitinib Malate is the only drug to break through the 2-year survival of advanced kidney cancer, and has a core position in the treatment of renal cell carcinoma and gastrointestinal stromal tumor. It was launched in the United States in February 2006. Sunitinib Malate is the first anti-cancer drug approved by the United States FDA to treat two diseases at the same time.
Applications/Functions of Sunitinib Malate powder
Sunitinib Malate powder is the first novel targeted drug that can selectively target multiple tyrosine kinase receptors, combining two mechanisms of action: anti-angiogenesis, which interrupts blood supply to tumor cells, and anti-tumor, which directly attacks tumor cells.
Physicochemical Property of Sunitinib Malate powder
